
Sign up to save your podcasts
Or
In this podcast, Dr. Valentin Fuster explores a study on the effects of SGLT2 inhibitors, like empagliflozin, on erythropoiesis and iron mobilization in heart failure patients. The research reveals how these drugs activate key metabolic pathways, potentially enhancing iron utilization and improving clinical outcomes, with significant implications for treatment in heart failure and chronic kidney disease.
4.2
154154 ratings
In this podcast, Dr. Valentin Fuster explores a study on the effects of SGLT2 inhibitors, like empagliflozin, on erythropoiesis and iron mobilization in heart failure patients. The research reveals how these drugs activate key metabolic pathways, potentially enhancing iron utilization and improving clinical outcomes, with significant implications for treatment in heart failure and chronic kidney disease.
131 Listeners
325 Listeners
864 Listeners
493 Listeners
22 Listeners
31 Listeners
3,332 Listeners
90 Listeners
137 Listeners
1,095 Listeners
61 Listeners
39 Listeners
185 Listeners
349 Listeners
427 Listeners